tiprankstipranks
Raymond James ups Regeneron to Market Perform as few downside catalysts remain
The Fly

Raymond James ups Regeneron to Market Perform as few downside catalysts remain

As previously reported, Raymond James analyst Dane Leone upgraded Regeneron to Market Perform from Underperform, arguing that there are "limited" remaining clinical downside catalysts during 2023. However, the firm said it expects continued debate around the outlook for Eylea, Vabysmo and 8mg aflibercept t weigh on the shares.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on REGN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles